Further studies are needed to investigate the prognosis and perioperative safety of patients undergoing robotic-assisted pancreaticoduodenectomy. In this study, clinical data and prognostic data of patients undergoing this procedure were prospectively collected and analyzed to explore its safety and efficacy.
Over 18 years old
Preoperative imaging suggested the presence of space occupying in the head of the pancreas, ampullary abdomen, and distal common bile duct tumor lesions to be treated with Pancreaticoduodenectomy
No distant transfer
No significant vascular invasion was received
With tumors of other organs
Patients unable to tolerate anesthesia and operation due to serious abnormalities in functions of heart, lung and other important organs
Patients found intraoperative peripheral organ metastasis combined with excision of other organs or found intraoperative radical excision could not be performed and underwent palliative drainage surgery or end the surgery
Preoperative adjuvant therapy was given
Single group
Robot-assisted Pancreaticoduodenectomy
Procedure/SurgeryBy performing pancreaticoduodenectomy on the subject using the latest generation Da Vinci robotic surgical system and assisted by another surgeon for the entire procedure
Rate of long-term Survival
survival will be documented 3 years after surgery
Unplanned re-admission rate after discharge within 30 days
Serious discomfort requiring re-admission within 30 days after discharge will be recorded, and the safety of the surgical method will be evaluated by this indicator
Incidence of postoperative complications
During hospitalization, common complications of pancreaticoduodenectomy, such as postoperative pancreatic fistula, bile leak, gastrojejunostomy leak, and delayed gastric emptying, will be recorded according to the international diagnostic criteria to evaluate the short-term safety of this surgical approach
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
